Table 3.
Studies assessing the effect of platelet-rich plasma (PRP) treatment in other patients in vitro fertilization.
| Year of Publication | Country | Year of Study | RCT | Objects | Sample Size | Intervention | Control | Time of PRP Infusion | Transfer Type | Outcome Measures | Effects | Reference | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case | Control | Cases/After PRP treatment | Control/Before PRP treatment | P Value* | ||||||||||||
| 2017 | India | January to August 2016 | No | Women aged 20-40 with suboptimal endometrial growth (endometrium thickness < 7mm despite standard dose of estradiol valerate (up to 16mg/day), or suboptimal endometrial vascularity (<5 vascular signals reaching the central zone (zones 3 and 4 as per Applebaum grading) of the endometrium), and repeated cycle cancellations | 64 | / | HRT+Intrauterine infusion of 0.5-0.8ml of PRP | / | On the 15th or 16th day of HRT cycle, and another dose 72h later if necessary | FET | Endometrial thickness (mm) | 7.22 | 5 | < 0.00001 | ↑ | (37) |
| Vascularity | sparse, modest → excellent vascularity pattern (17) sparse → modest vascularity pattern (52) persistant sparse vascularity pattern (4) |
/ | ||||||||||||||
| Serumβ-hCG positive | 39/64(60.93%) | 0/64 | / | |||||||||||||
| Clinical pregnancy | 29/64(45.31%) | 0/64 | / | |||||||||||||
| 2018 | China | January to October 2017 | No | Women aged 27-43 who underwent RIF with thin endometrium (<7 mm) or suboptimal endometrial vascularity with <5 vascular signals reaching the central zone (zones 3 and 4 as per Applebaum grading) | 20 | / | HRT+Intrauterine infusion of 0.5-0.8ml of PRP | / | Not mentioned | FET | Endometrial thickness | 7.82 ± 1.04 | 5.55 ± 0.71 | <0.0001 | ↑ | (21) |
| Pregnancy rate | 12/20(60%) | 0/20 | / | |||||||||||||
| 2018 | Venezuela | February 2016 to February 2017 | No | Women aged 33-45 with a history of refractory endometrium (characterized by atrophy with endometrial interface measurements below 6 mm by ultrasound; and/or the Asherman syndrome) and and at least one failed IVF attempt | 19 | / | HRT+Intrauterine infusion of 1ml of PRP | / | On the 10th day of HRT cycle, and then 72 hours after the first administration. | IVF-ET | Serumβ-hCG positive | 14/19(73.7%) | 0/19 | / | (38) | |
| Live birth | 5/19(26.3%) | 0/19 | / | |||||||||||||
| Ongoing pregnancy | 5/19(26.3%) | 0/19 | / | |||||||||||||
| Chemical pregnancy | 2/19(10.5%) | 0/19 | / | |||||||||||||
| Anembryonic pregnancies | 1/19(5.3%) | 0/19 | / | |||||||||||||
| Endometrial thickness | <7mm (with one dose);<9mm(with two doses) | Not mentioned | / | |||||||||||||
| 2018 | India | January 2018 to November 2018 | No | Women aged 25-40 who had at least one previous FET failure with endometrium 7 mm or more in thickness | 42 | 56 | HRT+Intrauterine infusion of 0.3-0.4ml of PRP | Underwent ET without intrauterine administration | On the 8th or 9th day of HRT cycle | FET | Clinical pregnancy | 47.6% | 42.8% | 0.09 | (-) | (39) |
*: ↑, increase; (-), no significant change.